Hematology Today—March 2, 2026

LucidQuest

9 hours ago

This is a weekly update in Hematology, covering key regulatory actions, clinical-trial progress, strategic financings, and emerging research across hematologic malignancies and rare blood disorders
Dive deeper

🩸 Johnson & Johnson seeks FDA approval of nipocalimab in wAIHA [1] [US • 24 Feb 2026]

https://www.jnj.com/media-center/press-releases/johnson-johnson-seeks-fda-approval-of-imaavy-nipocalimab-aahu-as-the-first-ever-fda-approved-treatment-for-warm-autoimmune-hemolytic-anemia-waiha
Context: Supplemental BLA supported by Phase 2/3 ENERGY trial in warm autoimmune hemolytic anemia.
Key point: Johnson & Johnson says nipocalimab produced rapid and durable hemoglobin responses with improved fatigue; if approved, it would be the first FDA-approved therapy for wAIHA.
Implication: May influence prescriber choice and payer reviews pending full data.

🧪 Cadrenal reports Phase 2 thrombotic event reduction with CAD-1005 in HIT [2] [US • 24 Feb 2026]

https://www.cadrenal.com/cadrenal-therapeutics-announces-phase-2-results-with-encouraging-reductions-in-thrombotic-events-for-cad-1005-in-hit-supporting-clinical-advancement/
Context: Phase 2 trial in heparin-induced thrombocytopenia did not meet its primary endpoint of platelet recovery.
Key point: Company reports >25% absolute reduction in thrombotic events versus placebo and plans End-of-Phase 2 FDA meeting in March 2026.
Implication: Could inform next-stage development and regulatory pathway discussions.

🧬 Fulcrum reports positive 12-week pociredir data in sickle cell disease [3] [US • 24 Feb 2026]

https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-announces-positive-12-week-results-20-mg
Context: Phase 1b PIONEER 20 mg cohort in sickle cell disease.
Key point: Mean fetal hemoglobin increased 12.2%; 58% achieved ≥20% HbF; hemoglobin rose by 1.1 g/dL; treatment was generally well tolerated. Registration-enabling study planned in H2 2026.
Implication: May influence prescriber choice and payer reviews pending full data.

🩸 Bristol Myers Squibb reports positive registrational Phase 2 luspatercept data in alpha-thalassemia [4] [US • 24 Feb 2026]

https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-Announces-Positive-Top-Line-Results-from-Registrational-Phase-2-Study-of-Luspatercept-in-Adults-with-Alpha–Thalassemia/default.aspx
Context: Study evaluated adults with non-transfusion-dependent and transfusion-dependent alpha-thalassemia.
Key point: Company reports statistically significant hemoglobin increases in non-transfusion-dependent patients and significant reductions in transfusion burden in transfusion-dependent patients.
Implication: May influence prescriber choice and payer reviews pending full data.

💊 C4 Therapeutics doses first patient in Phase 2 MOMENTUM trial in RRMM [5] [US • 23 Feb 2026]

https://ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-announces-first-patient-dosed-phase-2-momentum
Context: Single-arm study evaluating cemsidomide plus dexamethasone in relapsed/refractory multiple myeloma (~100 patients planned).
Key point: First patient dosed; primary endpoint is overall response rate; enrollment expected to complete in Q1 2027.
Implication: Signals pipeline investment in next-generation cereblon modulators.

🤝 Blackstone Life Sciences and Johnson & Johnson co-fund AML menin inhibitor development [6] [US • 23 Feb 2026]

https://www.blackstone.com/news/press/blackstone-life-sciences-announces-a-co-funding-agreement-for-acute-myeloid-leukemia/
Context: Research and development funding agreement to support clinical trials of bleximenib in AML.
Key point: Partnership will jointly finance ongoing and future studies of the investigational oral menin inhibitor.
Implication: Signals continued investment in targeted AML therapies.

🧬 Oryzon receives EMA approval to initiate Phase II iadademstat study in ET [7] [EU • 24 Feb 2026]

https://www.oryzon.com/en/news-events/news/oryzon-receives-european-medicines-agency-approval-initiate-phase-ii-study
Context: IDEAL study in essential thrombocythemia patients resistant or intolerant to hydroxyurea.
Key point: EMA authorized Phase II evaluation of LSD1 inhibitor iadademstat assessing safety, efficacy, and durable hematologic responses.
Implication: Expands epigenetic-targeted approaches in myeloproliferative neoplasms.

💰 Beam Therapeutics secures $500M strategic financing facility [8] [US • 24 Feb 2026]

https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-500-million-strategic-financing
Context: Financing with Sixth Street to support potential launch of risto-cel in sickle cell disease.
Key point: $100M funded at close with up to $400M milestone-based capital; structured as non-dilutive long-term financing.
Implication: Strengthens commercial readiness and capital position in gene-edited SCD therapy.

☢️ Pentixapharm receives FDA “Study May Proceed” letters for CXCR4 theranostic program [9] [US • 25 Feb 2026]

https://www.pentixapharm.com/news/pentixapharm-receives-fda-study-may-proceed-letters-for-dual-theranostic-inds-in-cxcr4-based-hemato-oncology-program
Context: Dual IND clearance for PentixaFor and PentixaTher.
Key point: PENTHERA Phase I/II trial will evaluate targeted CXCR4-based bone marrow conditioning prior to stem cell transplant in AML and multiple myeloma.
Implication: Signals pipeline investment and modality expansion.

🧬 Penn Medicine and CHOP publish CRISPR AML driver discovery platform [10] [US • 24 Feb 2026]

https://www.pennmedicine.org/news/crispr-based-platform-pinpoints-drivers-of-leukemia-in-patient-cells
Context: Published in Molecular Cell.
Key point: CRISPR-based platform enables high-throughput identification of AML genetic drivers directly in patient cells (~86% editing efficiency reported).
Implication: May expand personalized target discovery and translational research applications.

Why it matters

Regulatory momentum continues in rare hematologic diseases, including potential first-in-class approval efforts in wAIHA and registrational data in alpha-thalassemia.
Sickle cell disease remains a focal point across pharmacologic and gene-editing strategies, with both clinical progress and financing milestones.
AML innovation spans small molecules, precision conditioning, and functional genomics, reflecting sustained investment across modalities.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Hematology archive on our research hub page.

FAQ

What is the significance of the nipocalimab filing in wAIHA?

Johnson & Johnson submitted an sBLA supported by Phase 2/3 data; if approved, it would represent the first FDA-approved therapy for warm autoimmune hemolytic anemia. [1]

Did CAD-1005 meet its Phase 2 primary endpoint in HIT?

No. The study did not meet platelet recovery as the primary endpoint, but the company reports a >25% absolute reduction in thrombotic events. [2]

What were the key findings from the pociredir 12-week update?

Fulcrum reported a 12.2% mean increase in fetal hemoglobin, hemoglobin gains of 1.1 g/dL, and generally favorable tolerability in the 20 mg cohort. [3]

What did luspatercept show in alpha-thalassemia?

The registrational Phase 2 study met primary endpoints, with significant hemoglobin increases in non-transfusion-dependent patients and reduced transfusion burden in transfusion-dependent patients. [4]

Entities / Keywords

Johnson & Johnson, nipocalimab, FcRn, wAIHA, ENERGY
Cadrenal Therapeutics, CAD-1005, HIT, thrombosis
Fulcrum Therapeutics, pociredir, fetal hemoglobin, sickle cell disease
Bristol Myers Squibb, luspatercept, alpha-thalassemia
C4 Therapeutics, cemsidomide, RRMM
Blackstone Life Sciences, bleximenib, menin inhibitor, AML
Oryzon, iadademstat, LSD1 inhibitor, essential thrombocythemia
Beam Therapeutics, risto-cel, gene editing, financing
Pentixapharm, PentixaFor, PentixaTher, CXCR4, transplant conditioning
Penn Medicine, CHOP, CRISPR, AML drivers